BioMarin Pharmaceuticals BMRN FIRDAPSE — Revenue
Discontinued — last reported Q1 '26
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's firdapse — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's FIRDAPSE — revenue?
- BioMarin Pharmaceuticals (BMRN) reported FIRDAPSE — revenue of $219.88M in Q1 2026.
- How has BioMarin Pharmaceuticals's FIRDAPSE — revenue changed year-over-year?
- BioMarin Pharmaceuticals's FIRDAPSE — revenue increased by 2.9% year-over-year, from $213.75M to $219.88M.
- What does FIRDAPSE — revenue mean?
- The total sales revenue generated by a specific pharmaceutical product.
- How do you interpret FIRDAPSE — revenue?
- An increase suggests successful market penetration, expanded patient access, or effective commercial execution for the specific therapy. A decrease may indicate increased competition, patent expirations, or shifts in clinical treatment guidelines.
- How does FIRDAPSE — revenue compare across companies?
- Comparable to product-specific revenue lines reported by other specialty biopharmaceutical companies, often benchmarked against therapeutic area peers or orphan drug portfolios.